A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

Phase 3 Completed 1800 enrolled MedImmune LLC

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV-BFS; MEDI8662) was at least as immunogenic as two different forms of the commercial vaccine, FluMist, by comparing the strain-specific antibody levels in the blood.

Timeline

Start: 2009-08
Primary completion: 2010-01
Completion: 2010-03

Publications

Background Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky F, Mallory RM. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*. Influenza Other Respir Viruses. 2013 Nov;7(6):1142-50. doi: 10.1111/irv.12027. Epub 2012 Oct 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	FluMist/B/Victoria	Vaccine	0.2 ml	Intranasal
Comparator	FluMist/B/Yamagata	Vaccine	0.2 ml	Intranasal
Subject	MEDI8662	Vaccine	0.2 ml	—

Indications

No indication recorded.